Cynosure, Inc. (NASDAQ:CYNO) has been given an average recommendation of “Hold” by the nine analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $62.00.

Several research analysts recently commented on CYNO shares. Maxim Group downgraded Cynosure from a “buy” rating to a “hold” rating and set a $66.00 price objective for the company. in a research note on Tuesday, February 14th. Aegis downgraded Cynosure from a “buy” rating to a “hold” rating in a research note on Tuesday, February 14th. Northcoast Research raised Cynosure from a “sell” rating to a “neutral” rating in a research note on Tuesday, February 14th. Finally, Northland Securities reissued an “outperform” rating and issued a $60.00 price objective on shares of Cynosure in a research note on Thursday, February 16th.

Shares of Cynosure (NASDAQ CYNO) remained flat at $66.00 during midday trading on Monday. Cynosure has a 12-month low of $39.90 and a 12-month high of $66.65. The firm’s 50 day moving average price is $62.47 and its 200-day moving average price is $50.89.

TRADEMARK VIOLATION WARNING: “Cynosure, Inc. (CYNO) Receives $62.00 Consensus Price Target from Brokerages” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/cynosure-inc-cyno-receives-62-00-consensus-price-target-from-brokerages/1325599.html.

Hedge funds have recently modified their holdings of the company. FNY Partners Fund LP bought a new stake in shares of Cynosure during the first quarter worth about $1,326,000. Scout Investments Inc. increased its stake in shares of Cynosure by 25.7% in the first quarter. Scout Investments Inc. now owns 160,275 shares of the medical equipment provider’s stock worth $7,071,000 after buying an additional 32,750 shares during the period. Teachers Advisors LLC increased its stake in shares of Cynosure by 3.2% in the fourth quarter. Teachers Advisors LLC now owns 38,974 shares of the medical equipment provider’s stock worth $1,777,000 after buying an additional 1,193 shares during the period. Fortaleza Asset Management Inc. increased its stake in shares of Cynosure by 58.1% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,795 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 1,395 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in shares of Cynosure by 6.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 12,860 shares of the medical equipment provider’s stock worth $586,000 after buying an additional 800 shares during the period.

Cynosure Company Profile

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.